Allspring Global Investments
RLMD icon

Allspring Global Investments’s Relmada Therapeutics RLMD Stock Holding History

Allspring Global Investments’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-387
Closed -$7K – 2940
2022
Q2 		$7K Hold
387
– – ﹤0.01% 2600
2022
Q1 		$10K Buy
+387
New +$8K ﹤0.01% 2969

Other funds holding RLMD

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Allspring Global Investments's RLMD Position: Q3 2022 in Review

Allspring Global Investments sold out of Relmada Therapeutics (RLMD) in Q3 2022, closing a stake of 387 shares — an estimated $7K sold.

Allspring Global Investments first reported a position in RLMD in Q1 2022 and held it in 2 quarters. The position peaked at $10K in Q1 2022. 134 funds tracked by Wall St. Rank hold RLMD as of Q3 2022.

  • Allspring Global Investments reported no remaining Relmada Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Allspring Global Investments sold 387 Relmada Therapeutics shares in Q3 2022, an estimated $7K.
  • Allspring Global Investments first reported a position in Relmada Therapeutics in Q1 2022 and held it in 2 quarters.
  • Allspring Global Investments's Relmada Therapeutics position peaked at $10K in Q1 2022.
  • 134 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q3 2022.

Based on Allspring Global Investments's 13F filing for Q3 2022, filed 26 Oct 2022.